表紙:B細胞成熟抗原 (BCMA) 標的療法の世界市場 - 臨床試験の考察:2026年
市場調査レポート
商品コード
1035801

B細胞成熟抗原 (BCMA) 標的療法の世界市場 - 臨床試験の考察:2026年

Global B Cell Maturation Antigen (BCMA) Targeted Therapy Market & Clinical Trials Insight 2026

出版日: | 発行: KuicK Research | ページ情報: 英文 222 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=114.77円

ご注意: DRM (デジタル著作権管理システム) 付PDFになります。制限内容はお問合せください。
Multi-User License: 会社全体での使用権

B細胞成熟抗原 (BCMA) 標的療法の世界市場 - 臨床試験の考察:2026年
出版日: 2021年11月10日
発行: KuicK Research
ページ情報: 英文 222 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

がん研究は、従来のアプローチから脱却し、がん遺伝子を選択的に標的とすることで副作用を軽減した新薬の開発へと向かっています。ゲノム解析の結果、B細胞成熟抗原 (CD269) は、正常細胞と悪性細胞の両方に高いレベルで制限的に発現しており、多発性骨髄腫の新興治療薬を開発するための理想的な標的抗原であることが明らかになっています。

当レポートでは、世界のB細胞成熟抗原 (BCMA) 標的療法市場について調査分析し、市場分析、市場機会評価、販売考察、臨床試験の考察、主な市場力学、競合情勢などについて、体系的な情報を提供しています。

目次

第1章 BCMA標的療法のイントロダクション

第2章 BCMA標的療法の作用機序

第3章 BCMAは血液がんの理想的な標的

第4章 世界のBCMA標的薬市場分析

  • 概要
  • 将来の機会

第5章 世界のBCMA標的薬市場機会:地域別

  • 米国
  • 欧州
  • 日本
  • その他の地域

第6章 世界のBCMA標的薬市場:がんの種類別

  • 多発性骨髄腫
  • リンパ腫
  • 白血病

第7章 Blenrep (Belantamab Mafodotin-blmf) - 1番目に承認されたBCMA標的療法

  • 概要
  • 用量・価格分析
  • 販売分析

第8章 Abecma (Idecabtagene Vicleucel) - 2番目に承認されたBCMA標的療法

  • 概要
  • 用量、価格・販売分析

第9章 BCMA標的薬の販売予測:2026年

  • Blenrep
  • Abecma

第10章 BCMA標的薬の臨床試験の考察

  • フェーズ別
  • 開発状況別
  • 地域別

第11章 BCMA標的薬市場 - 進行中の研究開発

  • Ciltacabtagene Autoleucel (JNJ-68284528)
  • Allo715
  • CTX120
  • C-CAR088
  • CT053
  • HPN217
  • Pacanalotamab (AMG 420/ BI 836909)
  • PHE 885
  • bb21217
  • SEA BCMA

第12章 世界のBCMA標的薬の臨床試験の考察

  • 研究
  • 前臨床
  • 臨床
  • フェーズ0
  • フェーズI
  • フェーズI/II
  • フェーズII
  • フェーズII/III
  • フェーズIII
  • 事前登録

第13章 承認済みのBCMA標的薬の臨床考察

  • Belantamab Mafodotin - GlaxoSmithKline
  • Idecabtagene Vicleucel - Bluebird Bio/Celgene Corporation

第14章 世界のBCMA標的薬の市場力学

  • 市場促進要因
  • 市場課題

第15章 世界のBCMA標的薬市場の将来の見通し

第16章 競合情勢

  • Allogene Therapeutics
  • AbbVie
  • Amgen
  • BioTherapeutics
  • Bluebird Bio
  • Bristol Mayer Squibb
  • Carsgen Therapeutics
  • Celgene
  • Cogent Bioscience
  • CRISPR Therapeutics
  • GlaxoSmithKline
  • Harpoon Therapeutics
  • Hrain Biotechnology
  • iCell Gene Therapeutics
  • Johnson & Johnson
  • Juno Therapeutics
  • Novartis
  • Poseida Therapeutics
  • Seagen
  • Seattle Genetics
図表

List of Figures

  • Figure 1-1: Evolution of BCMA Targeting Therapeutics
  • Figure 2-1: BCMA Signaling Pathways
  • Figure 2-2: BCMA Targeting Therapeutics - Mechanism of Action
  • Figure 2-3: Blenrep - Mechanism of Action
  • Figure 2-4: Abecma - Mechanism of Action
  • Figure 3-1: Role of BCMA in Cell Cycle Signaling Pathway Regulation
  • Figure 3-2: Strategies For Targeting BCMA
  • Figure 3-3: Role of BCMA in Cancer
  • Figure 4-1: Global - Newly Diagnosed Leukemia Cases, 2020 - 2026
  • Figure 4-2: Global - Newly Diagnosed Hodgkin's Lymphoma Cases, 2020 - 2026
  • Figure 4-3: Global - Newly Diagnosed Non-Hodgkin's Lymphoma Cases, 2020 - 2026
  • Figure 4-4: Global - Newly Diagnosed Multiple Myeloma Cases, 2020 - 2026
  • Figure 4-5: Global - BCMA Targeting Therapy, Blood Cancer Therapeutics & Multiple Myeloma Therapeutics Market (US$ Billion), 2020
  • Figure 4-6: Global - BCMA Targeting Therapy Market Opportunity (US$ Million), 2020-2026
  • Figure 4-7: Global - Blood Cancer Drug Market Opportunity (US$ Billion), 2020-2026
  • Figure 4-8: Global - Multiple Myeloma Drug Market Opportunity (US$ Billion), 2020-2026
  • Figure 4-9: Global - BCMA Targeting Therapy Market by Product (%) 2026
  • Figure 5-1: US - Newly Diagnosed Leukemia Cases, 2020 - 2026
  • Figure 5-2: US - Newly Diagnosed Hodgkin's Lymphoma Cases, 2020 - 2026
  • Figure 5-3: US - Newly Diagnosed Non-Hodgkin's Lymphoma Cases, 2020 - 2026
  • Figure 5-4: US - Newly Diagnosed Multiple Myeloma Cases, 2020 - 2026
  • Figure 5-5: US - BCMA Targeting Therapy Market Opportunity (US$ Million), 2020-2026
  • Figure 5-6: US - BCMA Targeting Therapy Market by Product (%), 2026
  • Figure 5-7: Europe - Newly Diagnosed Leukemia Cases, 2020 - 2026
  • Figure 5-8: Europe - Newly Diagnosed Non-Hodgkin's Lymphoma Cases, 2020 - 2026
  • Figure 5-9: Europe - Newly Diagnosed Multiple Myeloma Cases, 2020 - 2026
  • Figure 5-10: Europe - BCMA Targeting Therapy Market Opportunity (US$ Million), 2020-2026
  • Figure 5-11: Europe - BCMA Targeting Therapy Market by Product (%), 2026
  • Figure 5-12: Japan - Newly Diagnosed Leukemia Cases, 2020 - 2026
  • Figure 5-13: Japan - Newly Diagnosed Hodgkin's Lymphoma Cases, 2020 - 2026
  • Figure 5-14: Japan - Newly Diagnosed Non-Hodgkin's Lymphoma Cases, 2020 - 2026
  • Figure 5-15: Japan - Newly Diagnosed Multiple Myeloma Cases, 2020 - 2026
  • Figure 5-16: Japan - BCMA Targeting Therapy Market Opportunity (US$ Million), 2022-2026
  • Figure 5-17: Japan - BCMA Targeting Therapy Market by Product (%), 2026
  • Figure 5-18: ROW - BCMA Targeting Therapy Market Opportunity (US$ Million), 2021 -2026
  • Figure 5-19: ROW - BCMA Targeting Therapy Market by Product (%), 2026
  • Figure 5-20: ROW - BCMA Targeting Therapy Market Share by Countries (%), 2026
  • Figure 6-1: Global - Number of Multiple Myeloma Cases, 2021-2026
  • Figure 6-2: Global - Multiple Myeloma Targeting BCMA Targeting Therapeutics Market Oportunity (US$ Million), 2021 - 2026
  • Figure 6-3: Global - Number of NHL Cases, 2021-2026
  • Figure 6-4: Global - Number of Hodgkin's Lymphoma Cases, 2021-2026
  • Figure 6-5: Global - BCMA Targeting Therapeutics Market Opportunity in Lymphoma (US$ Million), 2025 & 2026
  • Figure 6-6: Global - Number of Newly Diagnosed Leukemia Cases, 2021-2026
  • Figure 6-7: Global - BCMA Targeting Therapeutics Market Opportunity in Leukemia (US$ Million), 2025 & 2026
  • Figure 7-1: US - Blenrep FDA Approval & Orphan Designation Year
  • Figure 7-2: Europe - Blenrep EMA Approval & Orphan Designation Year
  • Figure 7-3: US - Price for 100mg Supply & Price for Single Treatment Cycle using Blenrep (US$), November'2021
  • Figure 7-4: Europe - Price for 100mg Supply & Price for Single Treatment Cycle using Blenrep (GBP), November'2021
  • Figure 7-5: Blenrep - Initial & Reduced Dose (mg/kg/3 Week)
  • Figure 7-6: Global - Blenrep Quarterly Sales Value (US$/GBP Million), Q1 - Q3, 2021
  • Figure 7-7: US - Blenrep Quarterly Sales Value (US$/GBP Million), Q1 - Q3, 2021
  • Figure 7-8: Europe - Blenrep Quarterly Sales Value (US$/GBP Million), Q1 - Q3, 2021
  • Figure 7-9: Global - Blenrep Sales Value by Region (US$/GBP Million), H1 2021
  • Figure 7-10: Global - Blenrep Half Yearly Sales Share by Region (%), H1 2021
  • Figure 7-11: Global - Blenrep Quarterly Sales Value by Region (US$/GBP Million), Q3, 2021
  • Figure 7-12: Global - Blenrep Quarterly Yearly Sales Share by Region (%), Q3, 2021
  • Figure 7-13: Global - Blenrep Quarterly Sales Value (US$/GBP Million), Q3 & Q4, 2020
  • Figure 7-14: US - Blenrep Quarter Sales Value (US$/GBP Million), Q3 & Q4, 2020
  • Figure 7-15: Europe - Blenrep Quarter Sales Value (US$/GBP Million), Q3 & Q4, 2020
  • Figure 7-16: Global - Blenrep Annual Sales Value by Region (US$/GBP Million), 2020
  • Figure 7-17: Global - Blenrep Sales Share in by Region (%), 2020
  • Figure 8-1: US - Abecma FDA Approval & Orphan Designation Year
  • Figure 8-2: Europe - Abecma EMA Approval & Orphan Designation Year
  • Figure 8 3: Abecma - Minimum & Maximum Dosage of CAR Positive Viable T Cells (Million ells), November'2021
  • Figure 8-4: Global - Abecma Quarterly Sales Value (US$ Million), Q2 & Q3, 2021
  • Figure 9-1: Global - Blenrep Sales Forecast (US$ Million), 2021 - 2026
  • Figure 9-2: US - Blenrep Sales Forecast (US$ Million), 2021 - 2026
  • Figure 9-3: Europe - Blenrep Sales Forecast (US$ Million), 2022 - 2026
  • Figure 9-4: Japan - Blenrep Sales Forecast (US$ Million), 2022 - 2026
  • Figure 9-5: ROW - Blenrep Sales Forecast (US$ Million), 2022 - 2026
  • Figure 9-6: Global - Abecma Sales Forecast (US$ Million), 2021 - 2026
  • Figure 9-7: US - Abecma Sales Forecast (US$ Million), 2021 - 2026
  • Figure 9-8: Europe - Abecma Sales Forecast (US$ Million), 2022 - 2026
  • Figure 9-9: Japan - Abecma Sales Forecast (US$ Million), 2022 - 2026
  • Figure 9-10: ROW - Abecma Sales Forecast (US$ Million), 2022 - 2026
  • Figure 10-1: Global - Number of BCMA Related Clinical Trials by Phase, November'2021
  • Figure 10-2: Global - BCMA Related Clinical Trials by Phase, November'2021
  • Figure 10-3: Global - Number of BCMA Related Clinical Trials by Development Status, November'2021
  • Figure 10-4: Global - Number of BCMA Related Clinical Trials by Development Status (%), November'2021
  • Figure 10-5: Global - Number of BCMA Related Clinical Trials by Region, November'2021
  • Figure 11-1: Investigational BCMA Targeting Therapeutics
  • Figure 11-2: CARTITUDE 1 Trial - Study Initiation & Completion Year
  • Figure 11-3: CARTITUDE 2 Trial - Study Initiation & Completion Year
  • Figure 11-4: CARTITUDE 4 Trial - Study Initiation & Completion Year
  • Figure 11-5: ALLO715 Phase I Trial - Study Initiation & Completion Year
  • Figure 11-6: CTX120 Phase I Trial - Study Initiation & Completion Year
  • Figure 11-7: C CAR088 Phase I Trial - Study Initiation & Completion Year
  • Figure 11-8: CT053 Phase II Trial - Study Initiation & Completion Year
  • Figure 11-9: CT053 Phase I Trial - Study Initiation & Completion Year
  • Figure 11-10: HPN217 Phase I Trial - Study Initiation & Completion Year
  • Figure 11-11: AMG 420 Phase I Trial - Study Initiation & Completion Year
  • Figure 11-12: PHE 885 Phase I Trial - Study Initiation & Completion Year
  • Figure 11-13: bb21217 Phase I Trial - Study Initiation & Completion Year
  • Figure 11-14: SEA BCMA Phase I Trial - Study Initiation & Completion Year
  • Figure 12-1: Global - number of BCMA Targeted Drug in Clinical trials, 2021 -2026
  • Figure 14-1: Global BCMA Targeting Therapy Market Drivers
  • Figure 14-2: Challenges for Global BCMA Targeting Therapy Market
  • Figure 14-3: US - Annual Cost Comparison of BCMA Targeting Therapy with other Treatments (US$), September'2021
目次

“Global B Cell Maturation Antigen (BCMA) Targeted Therapy Market & Clinical Trials Insight 2026 ” Report Analysis and Data Highlights:

  • Research Methodology
  • Global & Regional Market Analysis
  • Global BCMA Targeted Drugs Market Opportunity Assessment: > USD 4 Billion
  • Market and Drug Sales Insight 2020 Till 2026
  • Approved Drug In Market: 2 Drugs
  • Approved BCMA Targeted Drugs Patent, Price and Sales insight 2020 Till 2026
  • Future Market Assessment By Indication Till 2026
  • Ongoing Clinical Trials Assessment by Status, Phase & Region
  • Key Market Dynamics
  • Competitor Landscape

Over a period of time, the cancer research has deviated for conventional approach and is directed towards the development of novel drugs that selectively targets the oncogenes, thereby reducing the adverse side effects. Genomic analysis have shown that B-cell maturation antigen or CD269 is restrictively expressed in both normal as well as malignant cells at high levels, thus making it an ideal target antigen for development of novel multiple myeloma therapies. BCMA is a member of tumor necrosis factor family and has critical role in the regulating B-cell proliferation and survival. The interaction of BCMA with its ligand has also shown to promote the progression of cancer. Further, studies have also demonstrated that BCMA is central to the survival of multiple myeloma cells. Therefore, researchers have adopted several approaches to target this antigen as an alternative for the management of multiple myeloma.

Currently, multiple innovative BCMA-targeted treatment modalities, including antibody-drug conjugate (ADC), CAR-T cells, and bispecific T cell engager (BiTE), are under active clinical development. However, two BCMA targeted drug modalities have also entered the market. Belantamab mafodotin (Blenrep) developed by GlaxoSmithkline was the first BCMA targeted drug approved for patients with relapsed or refractory multiple myeloma who have received at least 4 prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent. It is an antibody drug conjugate which consists of humanized anti-BCMA IgG1 monoclonal antibody conjugated to monomethyl auristatin F (MMAF, mafodotin) via a non-cleavable maleimidocaproyl (MC) linker.

In April 2021, Abecma developed by Bristol Meyer Squibb has also gain entry into market for the management of multiple myeloma. Abecma is BCMA directed genetically modified autologous chimeric antigen receptor (CAR) T-cell therapy which is approved for the same indication. The entry of Abecma in the market is expected to have a negative impact on the growth of Blenrep sales which is mainly due to its novel mechanism of action, better survival rates, and ability to overcome the limitations of Blenrep. As per our analysis, Abecma will dominate the market during the forecast period. Apart from multiple myeloma, researchers are also evaluating the role of these drugs in other therapeutic conditions including AL Amyloidosis, and various subtypes of lymphoma which will further drive the growth of market. In addition, several ongoing clinical trials are also evaluating the use of Abecma in combination with other modalities including pembrolizumab, dexamethasone, and other chemotherapeutic agents which aim to enhance the efficacy of the treatment, which will boost this segment during forecast period.

The active research and development in this sector will drive the growth of the market. At present, several BCMA targeting drugs including ciltacabtagene autoleucel, Allo715, CTX-120, MCARH171, and others are present in clinical pipeline which are expected to gain approval during the forecast period. For instance, US FDA has recently granted priority review for ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy developed by Janssen. The rapid approval of these drugs during the forecast period will also drive the growth of market.

The global BCMA targeted drugs market is expected to witness high growth rates during the forecast period attributing mainly to the increase in prevalence of cancers and rates at which conventional therapies are failing. Moreover, key players in the market are strategically partnering and collaborating to expand the product portfolio and geographical presence of the company. Amid region, North America dominated the global market which is mainly credited to the growing number of research and development activities, presence of large pharmaceutical sector and high adoption rates of already approved therapies. Other regions such as Europe, Asia-Pacific are also expected to grow at high rates due to increase in prevalence of disorders and rising awareness among the population.

Table of Contents

1. Introduction to BCMA Targeting Therapy

  • 1.1 Overview
  • 1.2 History of BCMA Targeting Therapeutics

2. BCMA Targeting Therapeutics Mechanism of Action

3. BCMA As Ideal Target for Hematological Cancer

4. Global BCMA Targeting Drugs Market Analysis

  • 4.1 Overview
  • 4.2 Future Opportunity

5. Global BCMA Targeting Drugs Market Opportunity by Region

  • 5.1 US
  • 5.2 Europe
  • 5.3 Japan
  • 5.4 Rest of World

6. Global BCMA Targeting Drugs Market by Cancer Type

  • 6.1 Multiple Myeloma
  • 6.2 Lymphoma
  • 6.3 Leukemia

7. Blenrep (Belantamab Mafodotin-blmf) - First Approved BCMA Targeting Therapy

  • 7.1 Overview
  • 7.2 Dosage & Price Analysis
  • 7.3 Sales Analysis

8. Abecma (Idecabtagene Vicleucel) - Second Approved BCMA Targeting Therapy

  • 8.1 Overview
  • 8.2 Dosage, Price & Sales Analysis

9. BCMA Targeting Drugs Sales Forecast 2026

  • 9.1 Blenrep
  • 9.2 Abecma

10. BCMA Targeting Drugs Clinical Trials Insight

  • 10.1 By Phase
  • 10.2 By Development Status
  • 10.3 By Region

11. BCMA Targeting Drugs Market - Ongoing Research & Development

  • 11.1 Ciltacabtagene Autoleucel (JNJ-68284528)
  • 11.2 Allo715
  • 11.3 CTX120
  • 11.4 C-CAR088
  • 11.5 CT053
  • 11.6 HPN217
  • 11.7 Pacanalotamab (AMG 420/ BI 836909)
  • 11.8 PHE 885
  • 11.9 bb21217
  • 11.10 SEA BCMA

12. Global BCMA Targeted Drugs Clinical Trials Insight

  • 12.1 Research
  • 12.2 Preclinical
  • 12.3 Clinical
  • 12.4 Phase-0
  • 12.5 Phase-I
  • 12.6 Phase-I/II
  • 12.7 Phase-II
  • 12.8 Phase-II/III
  • 12.9 Phase-III
  • 12.10 Preregistration

13. Approved BCMA Targeted Drugs Clinical Insoght

  • 13.1 Belantamab Mafodotin - GlaxoSmithKline
  • 13.2 Idecabtagene Vicleucel - Bluebird Bio/Celgene Corporation

14. Global BCMA Targeting Drug Market Dynamics

  • 14.1 Market Drivers
  • 14.2 Market Challenges

15. Global BCMA Targeting Drug Market Future Outlook

16. Competitive Landscape

  • 16.1 Allogene Therapeutics
  • 16.2 AbbVie
  • 16.3 Amgen
  • 16.4 BioTherapeutics
  • 16.5 Bluebird Bio
  • 16.6 Bristol Mayer Squibb
  • 16.7 Carsgen Therapeutics
  • 16.8 Celgene
  • 16.9 Cogent Bioscience
  • 16.10 CRISPR Therapeutics
  • 16.11 GlaxoSmithKline
  • 16.12 Harpoon Therapeutics
  • 16.13 Hrain Biotechnology
  • 16.14 iCell Gene Therapeutics
  • 16.15 Johnson & Johnson
  • 16.16 Juno Therapeutics
  • 16.17 Novartis
  • 16.18 Poseida Therapeutics
  • 16.19 Seagen
  • 16.20 Seattle Genetics